• linkedin
  • Increase Font
  • Sharebar

    Investigational trials target VEGF/angiopoietin2 inhibition

    Results from preclinical and phase I trials suggest that dual inhibition of vascular endothelial growth factor (VEGF) and angiopoietin2 (Ang2) has potential benefit for treating retinal vascular diseases. The combined approach have progressed to Phase II studies.

    “Ang2 is a proangiogenic cytokine produced by endothelial cells,” explained Karl G. Casky, MD, PhD. “It is upregulated in pathologic neovascularization states, and its binding to the tyrosine kinase receptor, Tie2, on endothelial cells results in vessel destabilization and leakage.

     “Therefore, strategies to inhibit both VEGF, which is proangiogenic and increases vessel permeability, and Ang2 may provide a better approach than anti-VEGF treatment alone for achieving endothelial cell stabilization in retinal vascular diseases,” Dr. Casky added.

    Dr. Csaky is the T. Boone Pickens Director, Clinical Center of Innovation for AMD, and managing director and chief medical officer, Retina Foundation of the Southwest, Dallas, TX.

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';